Location：Home/News/Company NewsKeChow Pharma’s chemoprotective agent, HL-003, has received clinical approval from the National Medi
December 3, 2022, Shanghai - Today marked the online convening of the 2022 China Healthcare Summit o
On July 5, 2022, KeChow Pharma submitted an application for a pre-marketing communication meeting fo
KeChow Pharma announced that its MEK inhibitor, HL-085, for treating advanced NRAS-mutant melanoma,
The groundbreaking ceremony for KeChow Pharma Tianjin Branch’s innovative drug R&D laboratory was he
On August 2, 2021, Shanghai Roche Pharmaceuticals Ltd. (“Roche Pharmaceuticals China” or “Roche”) an
